| Date Filed | Type | Description |
| 02/23/2015 |
8-K
| Form 8-K - Current report |
| 02/23/2015 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 02/23/2015 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 02/20/2015 |
10-K/A
| Annual Report for the period ended December 31, 2014 [amend] |
| 02/18/2015 |
10-K
| Annual Report for the period ended December 31, 2014 |
| 02/17/2015 |
SC 13G/A
| JANUS CAPITAL MANAGEMENT LLC reports a 5.7% stake in NPS PHARMACEUTICALS, INC. |
| 02/17/2015 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 02/17/2015 |
SC 13G/A
| ING GROEP NV reports a 0% stake in NPS Pharmaceuticals, Inc. |
| 02/13/2015 |
SC 13G/A
| WELLS FARGO & COMPANY reports a 2% stake in NPS PHARMACEUTICALS INC |
| 02/13/2015 |
SC 13G/A
| FMR LLC reports a 15% stake in NPS PHARMACEUTICALS INC |
| 02/12/2015 |
SC 13G/A
| WELLINGTON MANAGEMENT GROUP LLP reports a 8.2% stake in NPS Pharmaceuticals, Inc. |
| 02/10/2015 |
SC 13G/A
| VANGUARD GROUP INC reports a 5.6% stake in NPS Pharmaceuticals Inc |
| 02/10/2015 |
SC 13G
| WELLS FARGO & COMPANY reports a 5.5% stake in NPS PHARMACEUTICALS INC |
| 02/10/2015 |
SC 13G/A
| WELLINGTON MANAGEMENT GROUP LLP reports a 3.1% stake in NPS Pharmaceuticals, Inc. |
| 02/10/2015 |
SC 13G/A
| FMR LLC reports a 4.3% stake in NPS PHARMACEUTICALS INC |
| 02/09/2015 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 01/29/2015 |
SC 13G/A
| BlackRock Inc. reports a 6.8% stake in NPS PHARMACEUTICALS INC |
| 01/28/2015 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 01/26/2015 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 01/23/2015 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 01/23/2015 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 01/16/2015 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 01/14/2015 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 01/13/2015 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 01/12/2015 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 01/12/2015 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 01/12/2015 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 01/12/2015 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 01/12/2015 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 01/12/2015 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 01/12/2015 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...|
Docs:
|
"Agreement and Plan of Merger, among NPS Pharmaceuticals, Inc., Shire Pharmaceutical Holdings Ireland Limited, Knight Newco 2, Inc. and Shire plc",
"Amended and Restated Bylaws of NPS Pharmaceuticals, Inc",
"Change in Control Severance Pay Plan, as amended on January 11, 2015",
"Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech" |
|
| 11/10/2014 |
10-Q
| Quarterly Report for the period ended September 30, 2014 |
| 11/10/2014 |
8-K
| Quarterly results |
| 11/04/2014 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
|